Species identification in hours instead of days, including deadly ESKAPE pathogens
The T2Bacteria® Panel is the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture.
50% of all bacterial bloodstream infections1
70% of all blood culture species in the emergency department2
90% of deadly ESKAPE pathogens3
Species identification in just hours: The commercially available T2Bacteria Panel provides species identification in 3 to 5 hours while the current standard of care takes 1 to 5 days or more.1 One T2Bacteria test result detects the equivalent of three sets of blood cultures for many species.2
Improved time to targeted therapy: By incorporating the Panel as part of the sepsis bundle, physicians can get more patients on the right therapy faster, thus improving empiric therapy protocols, potentially preventing the progression of sepsis, while increasing the chances of both patient survival and recovery.
Game-changing performance: In the T2Bacteria pivotal clinical trial1 conducted in 11 U.S. centers with 1,427 patients, investigators demonstrated:
Highly accurate results – identifying 3 times more infections than the paired blood culture draw
Positive and negative results more than 2 days faster than blood culture
Opportunities to de-escalate therapy and improve time to targeted therapy by days
Improved empiric therapy in the emergency department: Rapid diagnostics can significantly alter the early selection of appropriate therapy in patients with sepsis. Watch the 2018 video interview with two-time sepsis survivor Mary Millard, as she talks about her journey and how the T2Bacteria Panel test could have helped improve her outcome.
Contact us to request a demo of the T2Bacteria Panel!
………………………………………. 1. Nguyen, M. H., et al. Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. A Diagnostic Accuracy Study. Annals of Internal Medicine. 2019. 2. Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of emergency medicine 58.5 (2020): 785-796. 3. Karlowsky, JA, et al. Annals of Clinical Microbiology and Antimicrobials, 2004 * A combination of samples was run in both the prospective and contrived arms of the study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study, with an overall average PPA of 97% in the contrived arm of the study.
Sensitivity: 90%1,* Specificity: 98%1,*
E. faecium S. aureus K. pneumoniae A. baumannii P. aeruginosa E. coli
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.